Research programme: anti-Lewis Y monoclonal antibody - NEMOD
Alternative Names: Anti-Lewis Y monoclonal antibody research programme - NemodLatest Information Update: 15 Feb 2008
At a glance
- Originator NEMOD Biotherapeutics [CEASED]
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Apr 2006 No development reported - Preclinical for Cancer in Germany (unspecified route)
- 14 Jul 2004 Preclinical trials in Cancer in Germany (unspecified route)